Filing summary
Entity and period: The supplied filing is CopyTele, Inc.’s unaudited Form 10-Q for the quarter and six months ended April 30, 2012. This does not match the request metadata naming Anixa Biosciences Inc.; verify the issuer before relying on this summary.
Business context and financial results
CopyTele developed display technologies, including E-Paper and Nano Display, and encryption products. Its fiscal second-quarter results principally reflected license-fee revenue from AU Optronics Corp. (AUO); encryption-product sales were minimal.
| Metric | Three months ended Apr. 30, 2012 | Three months ended Apr. 30, 2011 | Six months ended Apr. 30, 2012 | Six months ended Apr. 30, 2011 |
|---|---|---|---|---|
| Revenue | $248,070 | $86,915 | $697,265 | $103,873 |
| Operating loss | $878,198 | $1,287,554 | $1,765,454 | $2,813,692 |
| Net loss | $877,109 | $1,287,040 | $1,763,194 | $2,813,149 |
| Net loss per share, basic and diluted | $0.00 | $0.01 | $0.01 | $0.02 |
Quarterly revenue included $246,670 of display-technology license fees and $1,400 of encryption sales. Six-month revenue included $693,340 of license fees and $3,925 of encryption sales. The filing does not provide a clear overall gross-margin figure.
Liquidity, cash flow, and balance sheet
- At April 30, 2012, cash and cash equivalents were $130,729 and short-term investments were $1,549,931, totaling approximately $1.68 million, down from approximately $3.02 million at October 31, 2011.
- Six-month operating cash use was $1,549,867; investing activities provided $698,106 and financing activities provided $208,450, primarily from stock-option exercises. Cash decreased by $643,311.
- Current assets were $1,788,159 versus current liabilities of $2,132,713, producing negative working capital of approximately $345,000. Excluding deferred AUO license revenue, management reported working capital of approximately $1.09 million.
- Total assets were $6,793,761. The balance sheet reported a $5 million related-party loan payable due in December 2014 and a matching $5 million loan receivable classified as contra-equity. Shareholders’ equity was negative $338,952.
- The Videocon investment was valued at $4,864,489, down $517,562 during the six months, with the unrealized loss recorded in other comprehensive loss rather than net income.
Changes, outlook, and risks
- Compared with the prior-year periods, six-month revenue rose mainly because AUO license revenue began being recognized; encryption revenue fell by about $100,000. Operating expenses declined, including research and development and selling, general and administrative expenses, contributing to a narrower net loss.
- AUO’s agreements provide for up to $10 million in license fees: $3 million was paid in 2011, while up to $7 million remains conditional on completion of specified conditions and subject to withholding tax. CopyTele recognized about $693,000 in license revenue in the first half; approximately $1.434 million remained deferred at April 30. The company said it could not estimate when, or whether, the remaining AUO fees would be received.
- Videocon’s agreement contemplated $11 million in license fees; CopyTele had received $3.2 million in total, with no payments in the periods presented. The filing reports uncertainty about future payment timing and describes discussions with Videocon, while the MD&A says substantive discussions were not then underway.
- Management believed available cash and investments, expected receipts, and possible expense reductions would support operations for at least 12 months from the reporting-period end. It cautioned that this depended on uncertain revenue and cash-flow projections; additional financing was not arranged, and any equity financing could dilute shareholders. Failure to secure funding or reduce costs could require curtailing or ceasing operations.
- Other notable risks include reliance on license fees and a concentrated customer base (one display customer accounted for 99.5% of total six-month revenue), product-development and commercialization uncertainty, and price and foreign-exchange exposure in the Videocon investment. A hypothetical 10% adverse combined move was estimated to reduce that investment’s fair value by approximately $486,000.
- The filing reported no material litigation, no material changes to previously disclosed risk factors, and effective disclosure controls as of period-end. Certain employees formerly compensated in stock began receiving cash compensation after January 2012.
Investor facts to verify
- Confirm that CopyTele, rather than Anixa Biosciences, is the issuer intended for review.
- Check the status, conditions, and expected timing of the remaining AUO fees and any royalties.
- Verify the collectability and payment schedule of Videocon’s deferred license fees.
- Assess liquidity against operating cash use, negative reported working capital, lease commitments, and the $5 million related-party obligation due in 2014.
- Review the valuation and market/foreign-exchange risks of the Videocon investment, and the potential dilution from stock-based compensation or future financing.